Magnesium valproate

Drug Profile

Magnesium valproate

Alternative Names: MagneVal

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator BioLink Life Sciences
  • Class Antiepileptic drugs
  • Mechanism of Action GABA uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Bipolar disorders; Epilepsy

Highest Development Phases

  • Clinical Phase Unknown Bipolar disorders; Epilepsy

Most Recent Events

  • 12 Aug 2016 Chemical structure information added
  • 04 Aug 2016 Magnesium valproate is available for licensing as of 04 Aug 2016. http://www.biolinkonline.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top